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Introduction 
 Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder 
characterized by various physical symptoms, including abdominal pain or discomfort and 
can be experienced in adjunction with abdominal distention and altered bowel function 
(Irritable Bowel Syndrome, 2013). It is the most common diagnosis among 
gastroenterologists and accounts for over 3.5 million visits to the physician per year (Best 
Ways to Battle Irritable Bowel Syndrome, 2014). IBS is diagnosed when a person has 
experienced abdominal pain or discomfort at least 3 times each month in the absence of 
other illness or injury. The pain may be associated with a change or consistency in stool 
frequency or be relieved by a bowel movement (Irritable Bowel Syndrome, 2013). 
Grundmann and Yoon (2010) estimated that IBS affects up to 20 percent of the adult 
population worldwide, although only up to 7 percent of adults with IBS are diagnosed; 
they also found that it demographically affects twice as many women as men, with most 
being under the age of 45 (as cited in Irritable Bowel Syndrome, 2013).  
 There are four main subtypes of IBS that implicate various distinguishing 
symptoms and subsequently, various unique treatments. The first two are the most 
common and include IBS with constipation (IBS-C), which is diagnosed based on 
experience of hard or lumpy stools at most of the time and loose or watery stools less 
often, and IBS-diarrhea (IBS-D), which is oppositely characterized by loose or watery 
stools more often and hard or lumpy stools less often (Irritable Bowel Syndrome, 2013). 
The last two subtypes are less common and include mixed IBS (IBS-M), which consists 
of hard or lumpy stools and loose or watery stools occurring equally often, and 
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unsubtyped IBS (IBS-U), which includes hard or lumpy stools and loose or watery stools 
occurring at irregular intervals (Irritable Bowel Syndrome, 2013).  
 From the division of subtypes it is apparent that a ‘one size fits all’ treatment will 
not be effective in managing symptoms of IBS, as the symptom experience varies 
drastically between subtypes. Therefore, clinicians face challenges in providing 
treatments that provide adequate control of symptoms. Though a wide variety of 
treatments exist, questions of effectiveness are constant, and patients are constantly 
seeking a better method of exacerbation prevention and symptom management. This 
review seeks to analyze current existing literature on the effectiveness of various 
interventions being used and/or tested to manage irritable bowel syndrome in adult 
patients. 
Literature Review 
 Methods of treating irritable bowel syndrome are still being developed today and 
range from western conventional practices to eastern alternative approaches.  
 Pharmacologic Therapies 
 Conventional pharmaceutical therapies consist of a few different drug classes with 
various rationales for use, including some separate drugs for each subtype of IBS that are 
mainly targeted at symptom reduction (Yoon, Grundmann, Koepp, & Farrell, 2011). 
Drugs used for general treatment of IBS including all subtypes are antispasmodics, which 
are the most common drugs, and antidepressants. Antispasmodics are antagonists at 
cholinergic receptors, thereby decreasing contraction of the GI tract. Antidepressants, 
surprisingly enough, work to normalize GI motility and reduce visceral pain. Though 
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originally thought to only work in treating co-existing mental disorders, clinical trials 
have shown effectiveness for all IBS patients. Classes like tricyclic antidepressants and 
selective serotonin reuptake inhibitors (SSRIs) are prescribed, and are thought to act on 
the neurochemical connection between the nervous system and the gastrointestinal tract 
that is widely hypothesized about in IBS research (Yoon et al., 2011).  Specifically for 
treating the IBS-D subtype, there are numerous recommended drugs, and most have the 
chief effects of decreasing intestinal motility and pain. 5-HT receptor antagonists are 
commonly used for this purpose, and some examples of medications are ondansetron and 
alosetron (Yoon et al., 2011). Selective M-receptor antagonists, such as samifenacin, are 
also used to decrease intestinal motility but have not been know to help with pain 
minimization. Other common classes are mu- opioid receptor agonists, like loperamide, 
and even alpha agonists, like clonidine (Yoon et al., 2011). Pharmacologic options for the 
IBS-C subtype differ and include drugs that have the primary effects of increasing 
intestinal motility and water secretion into the gastrointestinal tract. These drug classes 
include chloride channel modulators, like lubiprostone, and 5-HT agonists, which include 
drugs like tegaserod, metoclopramide, and domperidone (Yoon et al., 2011).  Laxatives 
and stool softeners have also been recommended, although adverse effects like electrolyte 
imbalances can occur, and the overall effectiveness of these drugs is limited (Yoon et al., 
2011). Drugs recommended for the IBS-M subtype act to increase compliance of the 
digestive tract, while also decreasing pain, but different classes have various effects on 
motility. For example, serotonergic and adrenergic receptor drugs like venlafaxine, have 
minimal effects on motility, but cholinergic receptor antagonists act to decrease motility, 
and include cimetropium, pinaverium, and hyoscine (Yoon et al., 2011). In general, 
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though prescription drug treatments have been useful to reduce symptoms, management 
of one symptom often has detrimental effects and increases the experience of other 
symptoms. Due to high placebo responses in randomized drug trials for IBS, efficacy of 
prescription drugs in general has been difficult to establish (Read, Rampersad-Smith, 
2013). 
 Alternative Therapies 
 As the experience of irritable bowel syndrome is extremely inconsistent from one 
patient experience to another and multiple aspects of life are affected as well as multiple 
types of symptom experiences, alternative therapies have become increasingly popular in 
recent years, as western healthcare in general is experiencing a change in focus from 
treatment to wellness. Multitudes of alternative therapies are surfacing, including 
activities as simple as exercise and as complex as acupuncture and psychotherapy. Other 
methods include ingestion of peppermint oil, adherence to diets targeted at decreasing 
IBS symptoms, mindfulness exercises and the use of probiotics. Results and effectiveness 
have been variable, but practitioners are seeing trends of increasing compliance and 
attention to general wellness in those who use alternative therapies in comparison to 
pharmacologic options (Staudacher, Whelan, Irving, & Lomer, 2011).   
 Diet alteration. Diet therapy has been the cornerstone of alternative therapy for 
IBS, and practitioners are shifting focus of first-line treatments from prescription drug 
therapy to diet modification. 
 Low FODMAPS diet. Arguably the diet modification with the most support at 
present is a diet low in rapidly-fermentable carbohydrates. This diet is called the low 
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‘fermentable oligosaccharides, disaccharides, monosaccharaides and polyols’ diet, also 
know as the low FODMAPS diet, and has seen success rates as high at 86% (Medlin, 
2012). Not only does the gut poorly absorb FODMAPS, but FODMAPS increase the 
amount of water drawn into the intestines and the bacteria in the colon rapidly ferment 
them, producing excess gas (Medlin, 2012).  
 (Medlin, 2012). 
These processes clinically manifest as typical IBS symptoms, like bloating, abdominal 
pain, changes in bowel habits, abdominal distention, and production of wind. Though a 
majority of people can consume a high FODMAP diet and have no problems, the existing 
visceral hypersensitivity and abnormal motility in those with IBS that FODMAPs trigger 
is what causes problems in patients. Rather, it is not the FODMAPs that cause IBS, but 
exacerbate symptoms in those with IBS (Medlin, 2012). Adherence to a low FODMAP 
diet involves first cutting out al FODMAP foods for 6-8 weeks and then slowly 
reintroducing some FODMAPs foods by consuming a small portion of the reintroduced 
food followed by a symptoms analysis and retrial. The goal is to reintroduce as many 
foods as possible without triggering symptoms. Foods like garlic, broccoli, and wheat or 
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rye bread are usually reintroduced fairly easily (Medlin, 2012). In a study done by the 
Nutritional Science Division at King’s College in London, 82 patients with established 
IBS by a primary care physician were seen by dieticians and either advised to consume a 
low FODMAPs diet or were given standard dietary advice for IBS based on diagnostic 
criteria- like regularly scheduled meals, slow consumption of meals, and incorporating 
fiber (Staudacher et al., 2011).  
  Over a period of 9 months, those on low FODMAPs diets reported significant 
improvement in symptoms compared to the standard group, with 82% experiencing 
improvement in bloating, 85% experiencing improvement in abdominal pain, and 87% 
experiencing improved rates of flatulence (compared to 49%, 61%, and 50% in the 
standard groups, respectively). Additionally, 28% of patients in the low FODMAPs group 
reported ‘moderate improvement’, and 47% reported ‘substantial improvement’ in terms 
of diarrheal symptoms, compared to 7% and 31% in the standard groups, respectively 
Staudacher et al., 2011). Only 14% of patients following the low FODMAPs diet 
experienced no change in symptoms, as compared to 51% of the standard group. Overall, 
75% of patients in the low FODMAPs group reported satisfaction with their symptom 
response (Staudacher et al.,2011). Despite the strong evidence implicated in the study, 
some drawbacks to the diet exist, as elimination of fruits and vegetables as well as lactose 
can lead to an imbalanced diet (Medlin, 2012). Thus it is vital that patients adhering to 
low FODMAPs diets continue to eat at least 5 or more portions of fruits and vegetables 
per day and seek dairy-free sources of calcium to promote bone health, as IBS patients 
are at increased risk of osteoporosis and fractures (Medlin, 2012).  Another drawback of 
the diet is that it hasn’t been found to improve outcome in patients with the IBS-C 
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subtype, thus other diet modifications may be better at decreasing constipation. 
Additionally, geographical locations influence the diet, as different countries consume 
different foods, and thus the list of FODMAP foods would need to be altered in each 
country to remain accurate (Medlin, 2012; Staudacher et al,, 2011).  The study performed 
by researchers at King’s College recommends for subsequent follow-up with a 
randomized controlled trial to further confirm the results (Staudacher et al,, 2011).   
 Probiotics. Another dietary approach to IBS symptom management that has 
become increasingly popular in the past few years is the consumption of probiotics. The 
World Health Organization defines probiotics as “…live microorganisms, that when 
administered in adequate amounts, have beneficial effects for the host” (as cited in 
Stevenson & Blaauw, 2011, p. 63). Though it is widely known that our digestive systems 
contain microflora, it is less known that over 500 different species of microbiota play a 
crucial role in metabolic processes required for digestion and wellness. The digestive 
system is colonized with these microbiota at birth, and many factors continue to play a 
role in the composition of organisms, like route of birth (cesarean vs. vaginal), use of 
antibiotics during the prenatal period, and breastfed versus bottle-fed practices after birth 
(Stevenson & Blaauw, 2011). These factors contribute to the permeability of the digestive 
tract as well as the types of microorganisms inhabiting the intestines. Dysbiosis, or a 
disturbance in the balance between host and microbiota can cause problems like 
inflammation, and thus, the microbiota in healthy patients versus patient with IBS differs 
greatly.  
 Balsari conducted a stool study of 20 IBS patients in which it was found that IBS 
stools contained less coliforms, lactobacilli, and bifidobacteria (as cited in Stevenson and 
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Blaauw, 2011).  Thus, the consumption of probiotic supplements with specific bacteria, 
such as lactobacillua plantarum and bifidobacterium infantis, has been recommended by 
researchers (Stevenson & Blaauw, 2011). Probiotics have been known to help with the 
secretion of antibacterial substances that decrease the luminal pH and decrease growth 
ability of pathogens, produce mucin that affects mucosal adherence of pathogens in the 
gastrointestinal tract, and increase the secretion if IgA that protects the microflora of the 
digestive system from bacterial attachment (Stevenson & Blaauw, 2011). Probiotics also 
ferment nutrients and subsequently acidify the colon, along with expressing receptors that 
sense bacteria and trigger appropriate immune responses to them (Stevenson & Blaauw, 
2011). In over 7 studies on probiotic use compiled by Stevenson and Blaauw, 
consumption of both L. plantarum and B. infantis was related to improvements in 
bloating, reduction in flatulence and pain, and bowel movement satisfaction (Stevenson & 
Blaauw, 2011).  
 Whorwell stated that evidence of the effectiveness of B. infantis prompted large, 
multi-centered research trials comprising over 360 patients with IBS that confirmed the 
symptomatic relief potential of the microorganism (as cited in Stevenson and Blaauw, 
2011). Stevenson and Blaauw (2011) emphasize that the various groupings of IBS 
provide barriers to effective treatment, as the different subtypes require different 
treatment considerations, and much of the current published data does not differentiate 
between subgroups, which complicates interpretation of research results. Additionally, 
although L. plantarum and B. infantis have been used in various research studies and 
trials, a study that combines the use of both of them as a “cocktail” hasn’t been conducted, 
which would be a valuable addition to existing evidence for the effectiveness of the two 
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strains. Gastrointestinal specialists in Canada completed an additional systematic review 
evaluating effectiveness of probiotics in IBS, and the results of over 918 participants with 
IBS in 10 different studies were evaluated and compared (Moayyedi, Ford, Talley, 
Cremonini, Foxx-Ornstein, Brandt, & Quigley, 2010). Results were that in all trials, 
participants reported a statistically significant reduction in pain. In 8 of the trials, 682 
patients reported an improvement in bloating, but this was not statistically significant. In 
six of the trials, 566 patients reported a statistically significant improvement in amount of 
flatulence, and three trials evaluating 394 patients found improvement in urgency, but 
this was not statistically significant (Moayyedi, et al., 2010). 
 Linaclotide. An additional dietary agent that has been used in symptom 
management of IBS is linaclotide. The Food and Drug Administration approved 
Linaclotide in 2012, and though implicated only in the IBS-C subtype, it has shown 
promising results in terms of decreasing constipation and difficulties associated with 
passing stool (Buono, Tourkodimitris, Sarocco, Johnston, & Carson, 2014).  IBS-C in 
particular has been associated with an average work productivity loss of 35.1%, which 
translated into 730 hours and $22,747 in lost costs annually for each patient employed 
with IBS-C (Buono, et al., 2014). IBS-C is defined as having >25% of bowel movements 
as being hard or lumpy and <25% of bowel movements occurring without the use of a 
laxative (Buono, et al., 2014). Supplementation of linaclotide in IBS-C patients has been 
associated with improved outcomes and symptom experience. Linaclotide is a minimally 
absorbed guanylate cyclase-C agonist, and it is a … “first class therapy approved for 
treatment of adult with IBS-C…” (Buono, et al., 2014, p.290). It acts by increasing 
chloride and bicarbonate secretions in the intestine and inhibits absorption of sodium, 
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increasing water secretion and therefore improving defecation (Love, Johnson, and Smith, 
2014).  
 Both Chey and Rao conducted multi-center studies that used linaclotide in adult 
patients with IBS-C and in both, significant improvement in abdominal and bowel 
symptoms was seen (as cited in Buono et al., 2014). Buono found that in a study of 
linaclotide vs. placebo over a 26-week period, treatment with linaclotide led to significant 
reductions from baseline in presenteeism of symptoms- with 15.7% of patients who 
received linaclotide reporting continuation of symptoms as compared to 21.5% of 
patients in the control group. Additionally, after 26 weeks, only 20.1% of the test group 
reported daily activity impairment as compared to 27.1% of the placebo group, and 
overall work productivity lost for linaclotide users was at 16.4% compared to 22.6% for 
the placebo group (Buono, et al., 2014). Linaclotide reduced overall work productivity 
loss by 2.4 hours weekly by week 26, which translates to a reduction in work productivity 
lost by 156 hours annually (Buono, et al., 2014).  
 An additional placebo-controlled study done by Andresen investigated linaclotide 
use in 36 patients over a period of 2 weeks, with patient diaries kept during and after 
treatment with linaclotide. Despite the short time period of treatment, overall ascending 
colon emptying was significantly improved with the use of 1000 micrograms of 
linaclotide daily, and time to first bowel movement, stool consistency, and stool passage 
were significantly improved (as cited in Love et al., 2014). Another study done by 
Johnston that used linaclotide versus placebo groups revealed that the average number of 
bowel movements experienced after 12 weeks of linaclotide increased to 3.61 as opposed 
to 1.01 for the placebo group (as cited in Love, et al., 2014). Drawbacks to linaclotide use 
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include a relatively high price, at approximately $277 per month. However, the 
mentioned trials demonstrated a statistically significant benefit with improved frequency 
of bowel movements and resolution of abdominal pain and bloating symptoms (Love, et 
al., 2014). As side effects are generally mild, linaclotide use has been an important 
advance in the treatment of IBS-C.  
 Anti-secretory factor. Other dietary approaches that exist in the literature, though 
one-of-a-kind studies have not been repeated in recent years, are the separate uses of anti-
secretory factor (ASF) and fasting therapy. ASF is a 41-kD protein that was originally 
studied by researchers in the 1980’s and originally resides in the rat pituitary gland, with 
both anti-inflammatory and anti-secretory effects (as cited in Ekesbo, Nilsson, & Sjolund, 
2008). Though first studied with use in piglets, it was eventually used in treatment of 
patients with inflammatory bowel disease and showed significant symptom improvement 
(Ekesbo et al., 2008). Thus, this study sought to evaluate ASF use in IBS patients and 
evaluate the self-assessed experience of symptoms. 82 patients with IBS who has average 
minimum pain scores of 40mm based on the Visual Analogue Scale (0-100mm) were 
evaluated. Half of participants were randomly selected to the test group and half to the 
control group, with test patients 3 receiving biscuits or crackers augmented with ASF per 
day and the control patients receiving the same foods equal in taste, but without the added 
ASF (Ekesbo et al., 2008).  Over a period of 8 weeks, results were evaluated and revealed 
the following: average number of bowel movements decreased from 1.7 to 1.6 per day, 
with over 40 patients experiencing decreased stool frequency and 26 experiencing 
increased frequency. These results were not deemed statistically significant due to a high 
placebo response, but an overall improvement in symptoms was found in both groups 
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(Ekesbo, et al., 2008). Thus, though efficacy isn’t confirmed, further research would need 
to be conducted to rule out ASF as a potential beneficial element in IBS treatment. 
 Fasting therapy. Fasting therapy has been described as a “…novel and simple 
psychotherapy…”, and was used in a pilot study in 2006 to look at whether IBS could 
also be improved by this eastern-style wellness technique (Kanazawa & Fukudo, 2006, 
p.214). In the study, patients in the traditional combination of pharmacotherapy and 
psychotherapy wasn’t effective were deemed intractable to treatment, and fasting therapy 
protocols or control group protocols were initiated.  
 The control group protocol consisted of the same traditional treatment previously 
received. A total of 36 individuals were admitted to private hospital rooms for 4 weeks 
that were part of the fasting group, and 22 individuals were outpatient status and 
continued to receive traditional treatment. In the fasting group, patients were subjected to 
10 days of starvation followed by 5 days of re-feeding (Kanazawa & Fukudo, 2006).  
Psychotherapy was also continued, and patients drank 1,000-2,000 mL of water each day 
to stay hydrated; tasteless hepatic and renal supplements were added to the water to 
prevent injury. Re-feeding began with 225 kcal and eventually increased to 2,100 kcal 
each day (Kanazawa & Fukudo, 2006). After the treatment period, results were that 
fasting therapy significantly decreased the scores of abdominal interference with life in 
general. Thus, out of the 10 symptoms targeted, fasting therapy improved 7 of 10. 
Improvements in constipation, depression, and somatoform were not statistically 
significant. With strong evidence of potential in improving IBS symptoms management, 
fasting therapy is convenient, as it provides a short therapeutic period and doesn’t require 
special skills on part of the physician.  Unfortunately, the evidence in the study needs to 
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be strengthened by additional studies, and no other studies of the nature have been 
conducted. Thus, although a seemingly promising component of IBS management, 
additional research needs to be completed to strengthen the evidence that fasting therapy 
is effective. Follow-up assessment was not completed after the study, and so a long-term 
prospective study would be ideal to examine the comprehensive effects of fasting therapy 
on IBS symptoms (Kanazawa & Fukudo, 2006). 
 Peppermint oil. An intervention therapy of additional prospective value is the use 
of peppermint oil in the treatment of IBS patients. Peppermint is a naturally occurring 
carminative of the mint family that causes relaxation of the gastrointestinal smooth 
muscle by blocking calcium channels (Khanna, MacDonald, & Levesque, 2014). 
Researchers began testing it for effectiveness in treatment of IBS after effectiveness was 
found in treating tension-type headaches, non-ulcer dyspepsia, and reduction of colon 
spasms (Merat, Khalili, Mostajabi, Ghorbani, Ansari, & Malekzadeh, 2010).  
 A primary experiment completed by researchers in a digestive diseases center 
involved IBS patients consuming peppermint oil extracted from the peppermint plant in 
enteric-coated capsules, called Colpermin. The double-blind, randomized placebo study 
utilized 187 mg capsules of Colpermin to be used three times daily 30 minutes before 
each meal for 8 weeks, while placebo group patients received capsules in 
indistinguishable boxes and were instructed to take the capsules on the same schedule. 
Results from 60 patients, 33 in the study group and 27 in the placebo group, revealed 
statistically significant data (Merat et al., 2010). At week 0, the time of introduction of 
the study, zero percent of participants reported being free of abdominal pain or 
discomfort. By week 8, 42.5% of patients in the study group reported being free from 
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abdominal pain and discomfort as compared to only 22.2% of the control group (Merat et 
al., 2010). Additionally, the intensity of abdominal pain and discomfort was significantly 
reduced in the study group, with a larger percent of study group patients experiencing 
occasional discomfort- 42% in the Colpermin group versus 22% in the placebo group- 
and a smaller percent in the study group experiencing persistent discomfort- 15% in the 
study group versus 52% of the control group (Merat et al., 2010).  
 The visual analogue scale (VAS) measures quality of life and was also completed 
by patients throughout the study, and results revealed significant improvement in quality 
of life for the study group versus the control group. The VAS was measured from 0-10 
with 10 being the optimal quality of life. Participants in the study group reported 
improvement in general quality of life at week 1, but significant improvement wasn’t 
noted until week 8. Comparing week 0 to week 8, quality of life for the study group had 
improved from 4.1 to 4.7 and had decreased in the control group from 5.8 to 4.0. Thus, 
this indicates a statistically significant improvement in bodily pain, general health, social 
functioning, and role limitation due to emotional problems (Merat et al., 2010). 
Researchers noted that the significant improvement in abdominal pain the in study group 
over the 8 week period could be the reason for the improvement in quality of life 
symptoms as well. From the study, it is concluded the peppermint oil is most effective in 
treating abdominal pain and subsequent overall quality of life (Merat et al., 2010). An 
additional meta-analysis on the use of peppermint oil capsules was conducted by 
researchers at both the Robarts Research Institute and the University of California San 
Diego (Khanna et al., 2014).  Randomized, placebo-controlled trials with a minimum of 
two weeks duration were considered, and nine studies using 726 patients were identified.  
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Five of those studies including 392 patients found a global improvement in IBS 
symptoms in 69% of patients receiving peppermint oil compared to 31% in the placebo 
groups (Khanna et al., 2014). Five of the nine studies, including 357 patients, found that 
57% of the patients receiving peppermint oil saw an improvement with abdominal pain 
compared with 27% of placebo patients (Khanna et al., 2014).  These results were found 
to be statistically significant. Those consuming peppermint oil in studies by both Khanna 
(2014) and Merat (2010) experienced some adverse events, and these included heartburn, 
headache, and dizziness; however, events were deemed mild and transient in nature. The 
meta-analysis by Khanna (2014) concluded that the studies showed safety and efficacy of 
peppermint oil used in patients with IBS but recommended that more long-term studies 
needed to take place to determine long-term safety and efficacy and to competently 
compare results with those of pharmacologic approaches, such as anti-spasmodics . 
 Psychological therapies. Though dietary approaches could be argued as the most 
logical tactics in treating a gastrointestinal illness like IBS, other methods of treatment, 
particularly psychological forms, have been explored with encouraging results. Most 
associated research indicates that although it is unlikely that psychological factors 
actually cause IBS, they appear to exert a strong influence on the lives of IBS patients. It 
has also been suggested that evidence of this strong influence indicates that investigating 
these psychological connections is clinically significant (Sugaya, Nomura, & Shimada, 
2012). Psychologically grounded research has been based on knowledge that the 
autonomic nervous system directly affects the gastrointestinal tract, which may lead to 
pain exacerbation and an increased feeling of anxiety. Consequentially, one can infer that 
those with IBS have higher anxiety and depression tendencies due to experience of 
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chronic, persistent pain (Smith, 2010). Additionally, background support for using 
psychological means to provide therapy for IBS patients comes from the idea that it treats 
the whole patient, which is most patient-centered way of care in any setting (Akbar, 
Desaid, Jenkins, Malley, Rampersad-Smith, Read, & Wiliams, 2013).  Multiple 
psychologically-based therapies have been recommended, including mainly mindfulness 
practices and cognitive-behavioral therapy.  
 Mindfulness. Mindfulness-based stress reduction (MBSR) is a psychosocial 
intervention, using biopsychosocial orientation. It consists of meditation practice and 
gentle hatha yoga stretches used in chronically ill populations. It seeks to cultivate… 
“conscious awareness in the present moment in an open and nonjudgmental manner…” 
(Zernicke, Tavis, Campbell, Blustein, Fung, Johnson, Bacon, & Carlson, 2013). It helps 
target processes such as rumination, worrying, and poor emotional regulation (Zernicke et 
al., 2013). 
 Burnett and Drossman discuss the idea of a link between the motor, sensory, 
intestinal, and central nervous systems called the ‘brain gut axis’ (as cited in Zernicke et 
al., 2013).  This implies a relation between sensation in the intestines and intestinal motor 
responses. Burnett and Drossman also note that since cognitive information and external 
stressors can affect GI sensations due to existing neural connections, increased GI 
muscular sensations can cause psychological distress because of amplified cognitive 
interpretations of these sensations (as cited in Zernicke et al., 2013). Zernicke (2013) 
cites multiples studies in the articles that have linked stress and exacerbation of IBS 
symptoms, inferring that emotional stress may trigger neuroimmune and neuroendocrine 
reactions via the brain gut axis (Zernicke et al., 2013). After a non-randomized trial was 
IRRITABLE	  BOWEL	  SYNDROME	  
	   17	  
conducted by Kearney that revealed a decrease in IBS-related quality of life and 
gastrointestinal-specific anxiety after 6 months of MBSR, Gaylord conducted a 
randomized trial of 75 women to either MBSR or social support (as cited in Zernicke et 
al., 2013). After 8 weeks, the MBSR group reported significant reductions in symptom 
severity following the intervention and at a 3-month follow up compared to the control 
group. Smith subsequently conducted a randomized treatment as usual (TAU) waitlist 
controlled trial based on these primary studies that tested not only the efficacy of MBSR 
in reducing stress and improving psychological well-being, but its effect on treating IBS 
symptoms as well. The trial was 8 weeks long and also consisted of a 6-month follow up 
period. All participants were currently being treated for IBS and were either assigned to 
the immediate MBSR intervention group, meaning that they were enrolled in the MBSR 
program over 8 weeks, or they were assigned to the TAU control group over 8 weeks and 
was scheduled to receive MBSR after the 6-month follow-up period. It was hypothesized 
that MBSR patients would experience greater reductions in IBS symptoms severity along 
with greater reduction in non-GI symptoms of stress, reduction in IBS symptoms, and 
increased quality of life (QOL) (Zernicke et al., 2013).  
 Results were that after 8 weeks of therapy for both groups, 50% of the MBSR 
group had a clinically significant improvement in symptoms as opposed to 21% of the 
TAU group. The MBSR group also reported a lower symptoms severity overall compared 
to the TAU group. Change scores were calculated, and the MBSR group experienced a 
30.7% reduction in IBS symptom severity immediately after the intervention, compared 
to only 5.2% of the TAU group (Zernicke et al., 2013). Overall, symptoms severity 
improvement changed from severe to moderate. This would practically mean that a 
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person went from constant, severe pain and frequently interfering pain symptoms with or 
without bowel distension to only occasionally experiencing these symptoms (Zernicke et 
al., 2013).  However, a notable weakness of the study was a rebound effect in symptoms 
for the MBSR group over the 6-month follow up period, whereas the control group 
continued to slowly improve overtime. This would suggest that the immediate effects of 
the MBSR program far exceed improvement rates without the intervention, but that this 
rate isn’t necessarily maintained over time if the intervention is stopped (Zernicke et al., 
2013). This allows the inference that the MBSR intervention is necessary to incorporate 
into one’s lifestyle as a long-term practice to maintain symptom improvement. The study 
also notes that the intervention would only work for those who expect a benefit and agree 
that stress is a contributing factor in symptom exacerbation of IBS. 
 Cognitive behavioral therapy. Cognitive behavioral therapy (CBT) is a 
psychological therapy involving talking that is useful for equipping the patient with 
problem-solving techniques and coping mechanisms (Dainty, 2012). As is applied to IBS, 
CBT has been thought to be a way of helping patients reason through their symptoms, 
their interpretation of their symptoms, and what can be done to improve that 
interpretation- therefore, indirectly improving symptoms. An article written by Ryle 
dating back to 1928 discusses the theory that IBS could be a physiological manifestation 
of emotional stress, and thus, the thought of this brain-gut connection is not new, but 
interventions that target IBS symptoms are recent additional treatment options. (as cited 
in Dainty, 2012).  
 Lydiard and Falsetti discussed that 50-90% of patients who have IBS also have a 
co-existing psychological condition, such as anxiety or depression (as cited in Dainty, 
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2012).  Multiple studies have connected IBS exacerbations and stressful life events, 
including anything from a transition to college and being independent to being a victim of 
sexual or emotional abuse (Dainty, 2012). Therefore, North hypothesized that CBT can 
help deal with issues like catastrophizing, meaning an irrational or exaggerated thoughts, 
and negative underlying thought patterns in general (as cited in Dainty, 2012). CBT 
corrects these maladaptive thought patterns in order to achieve positive changes in 
behavior and affect. Dainty discusses in his literature review that in 89.5% of the 
randomized control trials he reviewed (17 of 19 trials), results yielded were in favor of 
CBT (Dainty, 2012). However, he found lack of power and consistency in terms of 
reporting results, selecting participants, and measuring outcomes of the randomized trials, 
and suggests a need for further, consistent research parameters to strengthen the validity 
of results. Dainty suggests that CBT is a promising treatment in term of helping patients 
cope with symptoms and the impact of those symptoms on their quality of life but 
recommends further research (Dainty, 2012).  
 Interestingly enough, multiple sources suggested CBT as independent or adjunct 
therapy in the treatment of IBS, but structured randomized trials over periods longer than 
6 months with consistent inclusion parameters have either not been completed or are 
unpublished in the current literature. 
 Physical therapy. A final treatment that has been used in recent years to treat IBS, 
though not yet approved by national health institutes across the world, is a physical 
therapy called acupuncture for symptom management. Acupuncture is a traditional 
eastern medicinal approach that utilizes pricking of the skin with needles at various 
acupoints determined by the therapist. 
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   (Clinical Roundup, 2011). 
 It is known for alleviating pain and treating anything from physical, to mental and 
emotional issues, and is widely used in the Western hemisphere today, though use in IBS 
has only begun within the past ten years (Acupuncture, 2015).  
 As of 2012, 24 trials of acupuncture for IBS have been conducted, and results 
were promising in a majority of studies, but there was debate because of high placebo 
responses (Stuardi & MacPherson, 2012). A pragmatic randomized controlled trial was 
conducted with the intention of comparing symptoms severity after use of acupuncture 
compared with usual care, thought usual care was not explicitly defined (MacPherson, 
Tilbrook, Bloor, Brabyn, Cox, Kang’ombe, Man, Stuardi, Togerson, Watt, & Whorwell, 
2012). Symptom severity was measured using the IBS Symptom Severity Score (IBS 
SSS), which ranged numerically from 0-500, with scores less than 75 indicating no 
presence of IBS, 75-175 indicating mild IBS, 175-300 indicating moderate IBS, and 300-
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500 indicating severe IBS. It was determined that improvements by 50 points of more in 
the IBS SSS would be considered statistically significant improvements. Nine 
acupuncturists administered ten sessions of acupuncture each once a week over 10 weeks 
to the 116 participants in the acupuncture group while the 117 participants of the as usual 
group managed symptoms as advised by practitioners (MacPherson et al., 2012). Follow-
ups after the cessation of the study period were arranged for 3, 6, 9, and 12 months out. 
Results were that 49% of the acupuncture group experienced statistically significant 
improvement of symptoms over 10 weeks, compared to only 31% of the as usual group. 
Overall, the study found that acupuncture provided an adjunct small yet statistically 
significant benefit in IBS symptom reduction after 10 weeks (MacPherson et al., 2012). 
This study, implementing follow-ups for up to 12 months, was the most long-term of the 
studies completed implementing acupuncture in the treatment of IBS. Researchers 
hypothesized that the benefit seen at three months would remain the same if acupuncture 
were continued until month 12. Thus, it is recommended that acupuncture be an adjunct 
part of the therapy ‘cocktail’ for IBS management (MacPherson et al., 2012). 
Results 
The literature confirms that Irritable Bowel Syndrome doesn’t have a ‘one size fits all’ 
treatment regimen. Though all treatments are targeted at symptom management, methods 
vary according to the individual patient. 
 Pharmacologic, or more conventional methods, target symptom management and 
include antispasmodics, tricyclic antidepressants and SSRIs, 5-HT receptor and M-
receptor antagonists for IBS-D, channel modulators and 5HT-agonists for IBS-C, and 
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laxatives and stool softeners for IBS-C. Most classes of drugs function to alter gut 
motility, and others, like antidepressants and SSRIs, work to neutralize the relationship 
between the gut and the brain. Though multiple studies exist that test these drugs, 
efficacy of prescription drugs is still challenging to confirm. 
 Alternative therapies are trending, and many patients now are changing their 
lifestyles in one way or another rather than just taking a daily pill. As a major shift is 
occurring in western healthcare from treatment of illness to maintenance of wellness, 
patients are seeking to alter their lifestyles with therapies that are more natural and easier 
on the body. There are various alternative therapies that are increasingly common among 
patients with IBS, including diet alteration, psychological interventions, and physical 
therapies like acupuncture and yoga. 
 Diet alteration is one of the increasingly popular methods of symptom 
management, and includes the low FODMAPS diet, use of probiotics, incorporation of a 
dietary agent called Linaclotide, introduction of anti-secretory factor, fasting therapy, and 
the usage of peppermint oil capsules. The low FODMAPS diet eliminates certain types of 
carbohydrates that cause excess gas and irritation of the gut, and implementation of the 
diet has resulted in success rates as high as 86% (Medlin, 2012). The diet requires that 
patients eliminate all FODMAP foods for at least 6 weeks and then slowly reintroduce 
them to determine which specific foods are irritants. FODMAPS studies revealed 
significant improvements in the areas of flatulence, bloating, diarrhea, and abdominal 
pain. Probiotics are also commonly used to manage IBS, and the need for them arises 
from a state of dysbiosis that occurs in the guts of those with IBS. Probiotics are live 
organisms that are thought to restore the proper status of microbial biome in the gut. L. 
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plantarum and B. infantis were found to be the most effective probiotics in numerous 
studies examining IBS patients, with improvements found in bloating, flatulence, pain, 
and bowel movement satisfaction. The use of dietary linaclotide has also seen promising 
results. Linaclotide is a treatment designed specifically for patients with IBS-C, and it 
works to increase water absorption in the gut, adding water to the stool. Studies found 
that linaclotide created statistically significant improvements for patent with IBS-C, 
increasing work productivity, decreasing hours of work missed each week, and 
improving areas like time to first bowel movement, stool consistency, and stool passage. 
Anti-secretory factor has limited research backing up its results, but the most recent study 
from 2008 showed some evidence of effectiveness in treating IBS patients. It is a 
pituitary protein that, when incorporated into a study of patients with IBS, showed 
improvement in average number of bowel movements per day. The study wasn’t 
determined to be statistically significant due to a high placebo effect, but overall 
symptom improvement was seen in both the experimental and control groups. Fasting 
therapy is another alternative therapy lacking extensive research, but a pilot study in 2006 
used fasting therapy in the form of a 10-day starvation followed by half of that time in 
refeeding. Compared to a placebo group, patients who fasted experienced significant 
improvements in abdominal pain, bloating, flatulence, and bowel urgency. One additional 
dietary mechanism of treatment is the use of peppermint oil capsules for IBS symptom 
management. Peppermint, as a member of the mint family, relaxes the GI tract, improves 
dyspepsia, and reduces gut spasms. Results of multiple studies revealed that ingestion of 
peppermint oil resulted in significant improvement of abdominal pain and discomfort, 
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and overall quality of life, with up to 69% of trial participants experiencing improvement 
in these areas (Khanna et al, 2014). 
 Psychological approaches have also shown success in symptom management and 
control in patients with IBS. The two main therapies that have been implemented with 
significant results include mindfulness therapy and cognitive behavioral therapy. MBSR 
uses meditation and gentle yoga to provide biopsychosocial orientation, and it focuses on 
treating rumination, emotional regulation, and worrying. Results of a meta-analysis were 
that in numerous studies, up to 50% of patients receiving MBSR as compared to a 
treatment as usual group experienced significant reduction in symptom severity, 
including psychological well-being and stress reduction . Additionally, of symptoms still 
remaining, MBSR groups saw up to a 25% larger reduction in severity of remaining 
symptoms (Zernicke et al., 2013). CBT seeks to improve problem-solving techniques and 
coping mechanisms of patient with IBS. A meta-analysis of 19 experiments using CBT vs 
TAU groups in randomized trials revealed that almost 90% of trials had significant 
improvement in patient symptoms with use of CBT (Dainty, 2012). 
 An eastern medicinal approach that is also being studied in treatment of patients 
with IBS is the use of acupuncture. Acupuncture is known to alleviate pain by pricking 
the skin with needles, and has been known to improve physical, emotional, and mental 
health. A pragmatic trial studying acupuncture vs a TAU group, resulted in 49% of 
acupuncture participants experiencing improvement in symptoms after 10 weeks, as 
opposed to only 31% of the TAU group (MacPherson et al., 2012). 
Discussion 
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The multitude of symptoms and morbidities experienced by patients with IBS calls for 
close attention to regimens used to treat patients. From the literary evidence, it is apparent 
that there is no quick fix for IBS, and patients must be treated individually. Many of the 
trials cited report weakness in the strength of results used as a solo therapy and 
recommend that future researchers test treatment ‘cocktails’ instead, using multiple 
therapies that relieve different symptoms together. As all of the therapies discussed 
relieve only certain symptoms, it is evident that a combination of treatments, such as dual 
therapy including dietary and psychological approaches, may in adjunction treat more 
symptoms and improve quality of life. Additionally, as alternative therapies are 
increasingly popular, it is important for practitioners to be up-to-date with current 
literature so that treatment regimens are in sync with best practices. Thus, as there is a 
variety of evidence available on potentially effective single treatments, future research 
should focus on trials testing dual or triple therapies. In this way, holistic care of patient 
is provided, and different mechanisms for control can be implemented together to create 
the most effective symptom management possible. 
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